NEWS HIGHLIGHTS
Published Studies Related to Rhinocort Aqua (Budesonide Nasal)
The effect of nasally administered budesonide respules on adrenal cortex function in patients with chronic rhinosinusitis. [2009.03]
OBJECTIVES: To evaluate whether nasal administration of budesonide in adults with chronic rhinosinusitis for 30 days suppresses adrenal function and to assess its clinical efficacy... CONCLUSION: Our findings suggest that using budesonide nasal wash may be clinically effective in decreasing the symptoms of chronic rhinosinusitis and does so without suppression of the hypothalamic-pituitary-adrenal axis in patients with chronic rhinosinusitis.
Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. [2009.01]
BACKGROUND: Few studies have compared the effects of immunotherapy and inhaled steroids. The main limitation of such studies is the long duration required to fully appreciate the effects of immunotherapy. OBJECTIVE: To compare the effects of inhaled budesonide and sublingual immunotherapy (SLIT) in mild persistent asthma for up to 5 years... CONCLUSION: In patients with grass pollen-induced asthma, in the long term SLIT was equally effective as inhaled budesonide in treating bronchial symptoms and provided an additional benefit in treating rhinitis symptoms and bronchial hyperresponsiveness.
Effects of topical formoterol alone and in combination with budesonide in a pollen season model of allergic rhinitis. [2007.06]
BACKGROUND: beta(2)-Agonists may exert mast cell stabilizing and anti-plasma exudation effects. While available data suggest no or only marginal effects of beta(2)-agonists on symptoms of allergic rhinitis, little is known about whether these drugs may add to the efficacy of anti-rhinitis drugs. OBJECTIVE: To examine effects of a beta(2)-agonist, alone and in combination with an intranasal glucocorticosteroid, on symptoms and signs of allergic rhinitis... CONCLUSION: The present dose of formoterol does not affect symptoms and inflammatory signs of allergic rhinitis and does not add to the efficacy of topical budesonide.
Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. [2006.05]
BACKGROUND: Recent guidelines recommend intranasal corticosteroids as first-line treatment for managing persistent symptoms of moderate to severe allergic rhinitis (AR). However, in children, long-term continual treatment with corticosteroids has raised concerns about potential growth suppression. OBJECTIVE: To evaluate the effects of the recommended once-daily dose of budesonide aqueous nasal spray on growth velocity, as measured with stadiometry, in children with perennial AR... CONCLUSIONS: Treatment with budesonide aqueous nasal spray, 64 microg once daily, for 1 year did not suppress growth velocity compared with placebo and was well tolerated in prepubertal children with perennial AR.
A short course of oral prednisone followed by intranasal budesonide is an effective treatment of severe nasal polyps. [2006.05]
BACKGROUND: Nasal polyposis is an inflammatory disease of unknown etiology. This study aimed to evaluate the effect of a short course of oral prednisone followed by intranasal budesonide on nasal symptoms, polyp size, nasal flow, and computed tomography scan... CONCLUSION: A short course of oral steroids improved all nasal symptoms, polyp size, and nasal flow, whereas intranasal steroid maintain this effect.
Clinical Trials Related to Rhinocort Aqua (Budesonide Nasal)
Assess the Efficacy and Safety of Rhinocort Aqua [Completed]
The purpose of this study is to compare Rhinocort with placebo in pediatric subjects aged 2-5
years with allergic rhinitis to study effects on nasal symptoms such as sneezing, runny and
stuffy noses.
Rhinocort Aqua Versus Placebo and Fluticasone Propionate [Completed]
The purpose of this study is to compare once daily treatment with Rhinocort against placebo
and Fluticasone Propionate at reliving the nasal symptoms of seasonal allergic rhinitis.
Adults With Moderate to Severe Asthma [Completed]
A study to compare the safety and effectiveness of 5 different ways of taking Pulmicort when
given to asthma patients aged 12 years and above.
New Nasal Applicator / New Formulation - User Study [Completed]
The purpose of this study is to compare the efficacy of once daily dosing with Rhinocort
Aqua (new formulation) against Rhinocort Aqua (current formulation) and placebo in reliving
the symptoms of seasonal allergic rhinitis (SAR).
New Version Pulmicort Turbuhaler USA Children [Completed]
A comparison of the safety, efficacy and budesonide pharmacokinetics of the currently
approved Pulmicort Turbuhaler with a new version of the inhaler, in children and adolescents
who have asthma. In addition the study evaluated the functionality of the new inhaler at the
end of its intended life.
|
